ClinicalTrials.gg

Program

AK120

A development code. Also written as “AK120 300mg Q2W (JAK inhibitor users need to double the initial dose)”.

Its studies are mostly in Dermatitis, Atopic · Asthma, led by Akeso.

Furthest: phase 3, since Apr 21, 20247 company-led studies, 2 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Akeso72 open or runningphase 3since Apr 21, 2024Sep 9, 2021none ahead

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Sep 9, 2021First study: phase 2 study in Dermatitis, AtopicFirst studyNCT05048056 · 79 enrolled · United States, Australia, New Zealand
  2. Dec 1, 2021Phase 2 study in AsthmaNCT05155020 · 1 enrolled · China
  3. Jun 2, 2023Phase 2 study in Dermatitis, AtopicNCT06035354 · 427 enrolled · China
  4. Oct 16, 2023Phase 2 study in Dermatitis, AtopicNCT06092762 · 180 enrolled · China
  5. Apr 21, 2024Phase 3 study in Dermatitis, AtopicNCT06383468 · 420 planned · China
  6. Nov 14, 2024Phase 2 study in Dermatitis, AtopicNCT06700499 · 450 enrolled · China
  7. Dec 25, 2024Phase 2 study in Dermatitis, AtopicNCT06756126 · 24 planned · China

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 7 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06756126Dermatitis, Atopic · China2Not yet recruitingJun 30, 202524
NCT06700499Dermatitis, Atopic · China2CompletedJul 31, 2025450
NCT06383468Dermatitis, Atopic · China3RecruitingJan 30, 2025420
NCT06092762Dermatitis, Atopic · China2CompletedNov 13, 2024180
NCT06035354Dermatitis, Atopic · China2CompletedJun 21, 2024427
NCT05155020Asthma · China2TerminatedAug 5, 20221
NCT05048056Dermatitis, Atopic · United States, Australia, New Zealand2TerminatedMay 17, 202379

How it is read

Names in the registry

  • “AK120”, 16 entries
  • “AK120 300mg Q2W (JAK inhibitor users need to double the initial dose)”, 1 entry

Codes read as this program: AK120.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.